Divi’s Laboratories has reported robust financial results for the year ended March 31, 2026. The company achieved a consolidated total income of ₹11,067 crore for the fiscal year, representing a strong performance. Driven by this growth, the Board of Directors has recommended a final dividend of ₹30 per equity share, amounting to a 1,500% payout on the face value, subject to shareholder approval at the upcoming 36th Annual General Meeting.
Annual Financial Performance Highlights
For the financial year 2025-26, Divi’s Laboratories demonstrated significant financial growth. The company reported a consolidated total income of ₹11,067 crore, a notable increase compared to the ₹9,712 crore recorded in the previous fiscal year. Profit before tax (PBT) reached ₹3,388 crore, despite an incremental impact of ₹74 crore attributed to the implementation of new labour codes. Consequently, the Profit After Tax (PAT) for the year stood at ₹2,568 crore, up from ₹2,191 crore in the previous year.
Quarterly Results Overview
Performance in the fourth quarter (Jan-Mar 2026) remained strong, with a consolidated total income of ₹2,986 crore, compared to ₹2,671 crore in the same period last year. Profit after tax for the quarter was reported at ₹751 crore, showcasing solid operational stability. The results reflect the company’s sustained position in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients.
Dividend and Shareholder Meeting
Recognizing the company’s strong performance, the Board has recommended a final dividend of ₹30 per share for the financial year 2025-26. This dividend, based on a face value of ₹2 per share, represents a 1,500% return for shareholders. The payment is subject to approval at the 36th Annual General Meeting, which is scheduled to take place on August 10, 2026. Shareholders should note that July 24, 2026, has been designated as the record date for the purpose of dividend eligibility.
Source: BSE
